SARS-CoV-2 cell entry and targeted antiviral development
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the pandemic coronavirus disease 2019 (COVID-19), which threatens human health and public safety. In the urgent campaign to develop anti-SARS-CoV-2 therapies, the initial entry step is one of the most appealing ta...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-12-01
|
| Series: | Acta Pharmaceutica Sinica B |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211383521001726 |
| _version_ | 1818369602145484800 |
|---|---|
| author | Zinuo Chen Ruikun Du Jazmin M. Galvan Achi Lijun Rong Qinghua Cui |
| author_facet | Zinuo Chen Ruikun Du Jazmin M. Galvan Achi Lijun Rong Qinghua Cui |
| author_sort | Zinuo Chen |
| collection | DOAJ |
| description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the pandemic coronavirus disease 2019 (COVID-19), which threatens human health and public safety. In the urgent campaign to develop anti-SARS-CoV-2 therapies, the initial entry step is one of the most appealing targets. In this review, we summarize the current understanding of SARS-CoV-2 cell entry, and the development of targeted antiviral strategies. Moreover, we speculate upon future directions toward next-generation of SARS-CoV-2 entry inhibitors during the upcoming post-pandemic era. |
| first_indexed | 2024-12-13T23:26:27Z |
| format | Article |
| id | doaj.art-995cbc320d9844f69f3f96ddca474045 |
| institution | Directory Open Access Journal |
| issn | 2211-3835 |
| language | English |
| last_indexed | 2024-12-13T23:26:27Z |
| publishDate | 2021-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Acta Pharmaceutica Sinica B |
| spelling | doaj.art-995cbc320d9844f69f3f96ddca4740452022-12-21T23:27:32ZengElsevierActa Pharmaceutica Sinica B2211-38352021-12-01111238793888SARS-CoV-2 cell entry and targeted antiviral developmentZinuo Chen0Ruikun Du1Jazmin M. Galvan Achi2Lijun Rong3Qinghua Cui4College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, ChinaCollege of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China; Qingdao Academy of Chinese Medicinal Sciences, Shandong University of Traditional Chinese Medicine, Qingdao 266122, China; Experimental Center, Shandong University of Traditional Chinese Medicine, Jinan 250355, ChinaDepartment of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USADepartment of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA; Corresponding authors.College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China; Qingdao Academy of Chinese Medicinal Sciences, Shandong University of Traditional Chinese Medicine, Qingdao 266122, China; Experimental Center, Shandong University of Traditional Chinese Medicine, Jinan 250355, China; Corresponding authors.Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the pandemic coronavirus disease 2019 (COVID-19), which threatens human health and public safety. In the urgent campaign to develop anti-SARS-CoV-2 therapies, the initial entry step is one of the most appealing targets. In this review, we summarize the current understanding of SARS-CoV-2 cell entry, and the development of targeted antiviral strategies. Moreover, we speculate upon future directions toward next-generation of SARS-CoV-2 entry inhibitors during the upcoming post-pandemic era.http://www.sciencedirect.com/science/article/pii/S2211383521001726SARS-CoV-2Cell entrySpike proteinAntiviral developmentPost-pandemic |
| spellingShingle | Zinuo Chen Ruikun Du Jazmin M. Galvan Achi Lijun Rong Qinghua Cui SARS-CoV-2 cell entry and targeted antiviral development Acta Pharmaceutica Sinica B SARS-CoV-2 Cell entry Spike protein Antiviral development Post-pandemic |
| title | SARS-CoV-2 cell entry and targeted antiviral development |
| title_full | SARS-CoV-2 cell entry and targeted antiviral development |
| title_fullStr | SARS-CoV-2 cell entry and targeted antiviral development |
| title_full_unstemmed | SARS-CoV-2 cell entry and targeted antiviral development |
| title_short | SARS-CoV-2 cell entry and targeted antiviral development |
| title_sort | sars cov 2 cell entry and targeted antiviral development |
| topic | SARS-CoV-2 Cell entry Spike protein Antiviral development Post-pandemic |
| url | http://www.sciencedirect.com/science/article/pii/S2211383521001726 |
| work_keys_str_mv | AT zinuochen sarscov2cellentryandtargetedantiviraldevelopment AT ruikundu sarscov2cellentryandtargetedantiviraldevelopment AT jazminmgalvanachi sarscov2cellentryandtargetedantiviraldevelopment AT lijunrong sarscov2cellentryandtargetedantiviraldevelopment AT qinghuacui sarscov2cellentryandtargetedantiviraldevelopment |